Sunday, June 15, 2025
ISSN 2765-8767
  • Survey
  • Podcast
  • Write for Us
  • My Account
  • Log In
Daily Remedy
  • Home
  • Articles
  • Podcasts
    Navigating the Medical Licensing Maze

    The Fight Against Healthcare Fraud: Dr. Rafai’s Story

    April 8, 2025
    Navigating the Medical Licensing Maze

    Navigating the Medical Licensing Maze

    April 4, 2025
    The Alarming Truth About Health Insurance Denials

    The Alarming Truth About Health Insurance Denials

    February 3, 2025
    Telehealth in Turmoil

    The Importance of NIH Grants

    January 31, 2025
    The New Era of Patient Empowerment

    The New Era of Patient Empowerment

    January 29, 2025
    Physicians: Write Thy Briefs

    Physicians: Write thy amicus briefs!

    January 26, 2025
  • Surveys

    Surveys

    Perception vs. Comprehension: Public Understanding of the 2025 MAHA Report

    Perception vs. Comprehension: Public Understanding of the 2025 MAHA Report

    June 4, 2025
    Understanding Public Perception and Awareness of Medicare Advantage and Payment Change

    Understanding Public Perception and Awareness of Medicare Advantage and Payment Change

    April 4, 2025

    Survey Results

    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
  • Home
  • Articles
  • Podcasts
    Navigating the Medical Licensing Maze

    The Fight Against Healthcare Fraud: Dr. Rafai’s Story

    April 8, 2025
    Navigating the Medical Licensing Maze

    Navigating the Medical Licensing Maze

    April 4, 2025
    The Alarming Truth About Health Insurance Denials

    The Alarming Truth About Health Insurance Denials

    February 3, 2025
    Telehealth in Turmoil

    The Importance of NIH Grants

    January 31, 2025
    The New Era of Patient Empowerment

    The New Era of Patient Empowerment

    January 29, 2025
    Physicians: Write Thy Briefs

    Physicians: Write thy amicus briefs!

    January 26, 2025
  • Surveys

    Surveys

    Perception vs. Comprehension: Public Understanding of the 2025 MAHA Report

    Perception vs. Comprehension: Public Understanding of the 2025 MAHA Report

    June 4, 2025
    Understanding Public Perception and Awareness of Medicare Advantage and Payment Change

    Understanding Public Perception and Awareness of Medicare Advantage and Payment Change

    April 4, 2025

    Survey Results

    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
Daily Remedy
No Result
View All Result
Home Politics & Law

Serious About Expanding Access to Methadone

The Senate is scheduled to consider the Modernizing Opioid Treatment Access Act (MOTAA).

Jeff Singer by Jeff Singer
December 8, 2023
in Politics & Law
0
Serious About Expanding Access to Methadone

Priscilla Du Preez

Next Tuesday, December 12th, the Senate Committee on Health, Education, Labor, and Pensions (HELP) is scheduled to consider S.644, the Modernizing Opioid Treatment Access Act (MOTAA). The bill is sponsored by Senator Edward Markey (D‑MA) and co‐​sponsored by Senators Rand Paul (R‑KY), Bernie Sanders (I‑VT), Mike Braun (R‑IN), Cory Booker (D‑NJ), and Maggie Hassan (D‑NH). It would expand access to methadone treatment for people with opioid use disorder (OUD) by allowing board‐​certified addiction specialists to prescribe methadone to patients in their offices or clinics. This would provide people with an alternative option to the current system that segregates and stigmatizes people with OUD by making them queue up daily at government‐​approved opioid treatment programs (OTPs).

As I wrote here, the bill doesn’t go far enough—there are not nearly enough board‐​certified addiction specialists to meet the needs of people with OUD. However, as I wrote here:

The Modernizing Opioid Treatment Access Act is the first serious attempt in many years to remove unnecessary government barriers to methadone treatment. The bill also helps to destigmatize people with OUD by treating them as suffering from a medical condition.

As Sofia Hamilton and I explain in a recent Cato policy analysis, methadone has been proven as an effective treatment for addiction and dependency since the 1960s. Before Congress passed the Drug Abuse Prevention, Treatment, and Rehabilitation Act of 1972,  primary care clinicians in the US would prescribe methadone, an opioid agonist, to patients and follow them in their office practices.

That all ended in 1972 when the federal government segregated people with opioid use disorder from people with other health conditions that doctors treat in their offices, requiring them to often travel miles each day to take a daily dose of methadone in front of OTP staff. In the UK, Canada, and Australia, primary care clinicians working with community pharmacies have always prescribed methadone, and people in those countries thus have much greater access to methadone treatment.

Ideally, Congress should allow primary care clinicians to prescribe methadone to people with OUD in the office setting, as they do in the countries above. Clinicians can already prescribe another opioid agonist medication, buprenorphine, in the office to treat OUD. And we doctors can legally prescribe methadone to treat patients’ pain in the office setting. There is no good reason for the government to apply different rules for prescribing methadone to treat OUD.

 

methadone treatment, oud

Most objections to allowing clinicians to prescribe methadone emanate from the operators of the OTPs. This comes as no surprise. It is reminiscent of the objections raised by the taxi cartels when Uber and Lyft emerged as competition. They argue that allowing clinicians to prescribe take‐​home methadone—and pharmacists to fill the prescriptions—would result in methadone getting “diverted” to the black market for sale to non‐​medical drug users. But the evidence doesn’t back up those claims.

Critics of allowing clinicians to prescribe buprenorphine raised similar concerns about diversion. But research in 2018 by Washington University’s Theodore Cicero and others shows:

The most common reasons for illicit buprenorphine use were consistent with therapeutic use: to prevent withdrawal (79%), maintain abstinence (67%), or self‐​wean off drugs (53%)… Among respondents who had used diverted buprenorphine, 33% reported that they had issues finding a doctor or obtaining buprenorphine on their own. Most (81%) of these participants indicated they would prefer using prescribed buprenorphine, if available.

The researchers concluded, “Diversion was partially driven by barriers to access, and an unmet need for OUD treatment persists.”

In March 2020, the Substance Abuse and Mental Health Services Administration (SAMHSA) temporarily liberalized methadone take‐​home rules for OTPs, allowing “stable” patients to take home up to a 28‐​day supply. The program was such a success that SAMHSA has extended the rule and is “working toward a permanent solution.” Researchers at the Centers for Disease Control and Prevention and the National Institute on Drug Abuse evaluated the impact of the relaxed take‐​home rules and wrote in JAMA Psychiatry in July 2022, “Monthly methadone‐​involved overdose deaths remained stable after March 2020.”

The National Institutes of Health reported that same month that “the percentage of overdose deaths involving methadone declined between January 2019 and August 2021.”

Interestingly, the National Institute on Drug Abuse stated in December 2021:

Methadone diversion is primarily associated with methadone prescribed for the treatment of pain and not for the treatment of opioid use disorders. In one survey, giving methadone away was identified as the most common form of methadone diversion, which aligns with other findings that 80 percent of people who report diverting methadone did so to help others who misused substances. (Emphasis added.)

Keep in mind that the law has always permitted clinicians to prescribe methadone for the treatment of pain.

Thus, it appears that, as with buprenorphine, the majority of people who use diverted methadone are using it to avoid withdrawal as they attempt to taper off of an illicit opioid they’ve been using. This is because they cannot get access to the scarce number of methadone OTPs.

As I pointed out here, ”Expanding access to OUD treatment would reduce the number of people who seek drugs in the dangerous black market and, in turn, reduce the risk and incidence of overdose deaths.”

Last September, I moderated a policy forum at the Cato Institute examining ways to expand access to methadone treatment that featured Rep. Donald Norcross (D‑NJ), a sponsor of the House version of MOTAA. You can view it here.

As the Senate HELP Committee starts to mark up the bill, lawmakers should dismiss unsubstantiated concerns about diversion that incumbent OTP operators would like to raise. On the contrary, based on the data, one can argue that the most effective way to minimize methadone diversion is to increase access to methadone treatment.


This article first appeared at the Cato At Liberty blog site.

Source: Cato At Liberty
ShareTweet
Jeff Singer

Jeff Singer

Jeffrey A. Singer is a senior fellow at the Cato Institute and works in the Department of Health Policy Studies. He is President Emeritus and founder of Valley Surgical Clinics Ltd., the largest and oldest group private surgical practice in Arizona, and has been in private practice as a general surgeon for more than 35 years.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Videos

Summary

In this episode of the Daily Remedy Podcast, Dr. Joshi discusses the rapidly changing landscape of healthcare laws and trends, emphasizing the importance of understanding the distinction between statutory and case law. The conversation highlights the role of case law in shaping healthcare practices and encourages physicians to engage in legal advocacy by writing legal briefs to influence case law outcomes. The episode underscores the need for physicians to actively participate in the legal processes that govern their practice.

Takeaways

Healthcare trends are rapidly changing and confusing.
Understanding statutory and case law is crucial for physicians.
Case law can overturn existing statutory laws.
Physicians can influence healthcare law through legal briefs.
Writing legal briefs doesn't require extensive legal knowledge.
Narrative formats can be effective in legal briefs.
Physicians should express their perspectives in legal matters.
Engagement in legal advocacy is essential for physicians.
The interpretation of case law affects medical practice.
Physicians need to be part of the legal conversation.
Physicians: Write thy amicus briefs!
YouTube Video FFRYHFXhT4k
Subscribe

MD Angels Investor Pitch

Visuals

Official MAHA Report

Official MAHA Report

by Daily Remedy
May 31, 2025
0

Explore the official MAHA Report released by the White House in May 2025.

Read more

Twitter Updates

Tweets by DailyRemedy1

Newsletter

Start your Daily Remedy journey

Cultivate your knowledge of current healthcare events and ensure you receive the most accurate, insightful healthcare news and editorials.

*we hate spam as much as you do

Popular

  • The Grey Market of Weight Loss: How Compounded GLP-1 Medications Continue Despite FDA Crackdowns

    The Grey Market of Weight Loss: How Compounded GLP-1 Medications Continue Despite FDA Crackdowns

    0 shares
    Share 0 Tweet 0
  • The First FBI Agent I Met

    3 shares
    Share 0 Tweet 0
  • Retatrutide: The Weight Loss Drug Everyone Wants—But Can’t Officially Get

    1 shares
    Share 0 Tweet 0
  • The Southern Signal: Australia’s Flu and COVID Wave Could Foreshadow America’s Next Public Health Crisis

    1 shares
    Share 0 Tweet 0
  • When Influence Turns Deadly: The Cancer Misinformation Crisis on Social Media

    1 shares
    Share 0 Tweet 0
  • 628 Followers

Daily Remedy

Daily Remedy offers the best in healthcare information and healthcare editorial content. We take pride in consistently delivering only the highest quality of insight and analysis to ensure our audience is well-informed about current healthcare topics - beyond the traditional headlines.

Daily Remedy website services, content, and products are for informational purposes only. We do not provide medical advice, diagnosis, or treatment. All rights reserved.

Important Links

  • Support Us
  • About Us
  • Contact us
  • Privacy Policy
  • Terms and Conditions

Newsletter

Start your Daily Remedy journey

Cultivate your knowledge of current healthcare events and ensure you receive the most accurate, insightful healthcare news and editorials.

*we hate spam as much as you do

  • Survey
  • Podcast
  • About Us
  • Contact us

© 2025 Daily Remedy

No Result
View All Result
  • Home
  • Articles
  • Podcasts
  • Surveys
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner

© 2025 Daily Remedy

Start your Daily Remedy journey

Cultivate your knowledge of current healthcare events and ensure you receive the most accurate, insightful healthcare news and editorials.

*we hate spam as much as you do